Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02738047 · ClinicalTrials.gov registry record
Reduction of Adverse Drug Events and Readmissions
A clinical trial of Pharmacogenomic Testing for Medication Management, sponsored by ClinLogic.
- Recruiting
- Registry status
- 280,000
- Enrollment target
- 1
- Study location
NCT02738047: Recruiting study of Pharmacogenomic Testing for Medication Management, sponsored by ClinLogic.
NCT02738047 is a study of Pharmacogenomic Testing for Medication Management that is actively recruiting participants, run by ClinLogic. The registered enrollment target is 280,000 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02738047, a study of Pharmacogenomic Testing for Medication Management, is actively recruiting participants, sponsored by ClinLogic.
- RECRUITING
- Registry status
- 280,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
Primary Outcome
The primary endpoint of the study is the binary occurrence of meaningful change in drug regimen, defined in each patient when: 1. A genotype known to affect a drug the patient is taking is identified, \*and\* 2. The patient's treating physician makes at least one target drug regimen change, dose, substitution, or discontinuation. Change in drug dose, substitution, or discontinuation among patients with an identified genotype known to affect a drug the patient is taking as directed. This will b
Conditions Studied
Study Locations (1)
Pennsylvania
- MD@Home - York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280,000 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2026-12 |
What NCT02738047 shows while recruiting
NCT02738047 is an observational study that tracks outcomes without assigning an intervention. Its 280,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Pharmacogenomic Testing for Medication Management appearing as the primary indexed condition, and to 0 interventions.
NCT02738047 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02738047 about?
NCT02738047 is a clinical study titled "Reduction of Adverse Drug Events and Readmissions". Pharmocogenomic test assessment in the medication regimen and disease management for patients under drugs known with genetic variation.
What is the current status of trial NCT02738047?
This trial is currently recruiting. The enrollment target is 280,000 participants. The study started on 2019-03-15. Estimated completion is 2026-12.
What conditions does trial NCT02738047 study?
This clinical trial studies the following conditions: Pharmacogenomic Testing for Medication Management.
Who is sponsoring clinical trial NCT02738047?
This trial is sponsored by ClinLogic, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02738047 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02280733 · 300,000 participants
A Real-World Registry of Chronic Wounds and Ulcers
- NCT06694181 · 300,000 participants
Safe and Explainable AI
- NCT07314697 · 300,000 participants · NA
Arrival Time Implementation
- NCT05365048 · 301,201 participants · NA
Provider Recommendation and HPV Vaccination
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI